Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Stainwei Biotech

Next Previous
Search
Drug Profile

Research programme: cancer therapeutics - Stainwei Biotech

Alternative Names: hAB 21; M23; P16

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stainwei Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Placenta growth factor inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 May 2019 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
  • 03 May 2017 hAB 21 is still in preclinical development for Cancer in China
  • 03 May 2017 Stainwei Biotech announces intention to submit IND for hAB 21 to the China FDA for Solid tumours (Late-stage disease) in the second half of 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top